NWO Graduate Programme
Future medicines: advanced affordable biomolecular and cellular therapies
As of September 2016 we will start the Graduate Programme, supported by NWO. The aim is to create a cohort of PhD candidates, to promote the advanced affordable biomolecular and cellular therapies, and to strengthen our UIPS community. We want to stimulate master students to write their own PhD research proposal and to interact with as many research groups as possible through rotation. An example of Future medicines can be found in this movie, focusing on delivery of genes.
A focus group of PhD students with an interest in biopharmaceuticals,cell and gene therapy, the Future Medicines Fellows, is selected and allowed to participate in the Principal Investigator (PI) rotation. The same group will manage and organize the meetings and topics of the Future Medicines Lecture Series, as well as a Future Medicines Summer School, which is open to all. We foresee that our future medicines will be advanced biomolecular and cellular therapies. These biopharmaceuticals can be proteins, nucleic acids, carbohydrates, lipids and even cells. The ultimate aim is to offer personalised or precision medicine. More and more drugs will be registered with a companion diagnostic. Affordability is another scientific challenge in precision medicine.
Lourens Bloem
Adaptive pathways, a changing role for pharmacovigilance
Gerlof Bosman
Chemoenzymatic glycoengineering of biotherapeutics
Donna Debets
Development of a targeted phosphoproteomics assay to accurately predict drug response in breast cancer patients
Charlotte van Gelder
High-resolution (phospho)proteomics of serotonergic neuronal differentiation and maturation in psychiatric disease using patient-derived induced pluripotent stem cells.
Katja Jansen
3D printed kidney tubes for renal function replacement.
Saar van der Laarse
Probing the function and drug-ability of Pin1; a protein relevant for stem cell differentiation, cancer and Alzheimer disease
Carl Schuurmans
Cell-friendly aqueous microfluidics for stem cell therapies
Rick Vreman
Early health technology assessment; a tool for increased expediency in drug development and reimbursement.
Tom Wood
Identification, synthesis, and improvement of novel antibiotics targeting drug-resistant bacteria